Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1775-1781

  Wunder, Frank ^a   Tersteegen, Adrian ^a   Rebmann, Annegret ^a   Erb, Christina ^a   Fahrig, Thomas ^a   Hendrix, Martin ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROPHENYL) 6 (3,3,3 TRIFLUORO 2 METHYLPROPYL) 1,5 DIHYDRO 4H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 4 [[4 CARBOXYBUTYL [2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL] BENZOIC ACID; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 9 (2 HYDROXY 3 NONYL)ADENINE; BAY 73 6691; CATION CHANNEL; CYCLIC GMP; DIPYRIDAMOLE; GUANYLATE CYCLASE INHIBITOR; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IX INHIBITOR; ROLIPRAM; TADALAFIL; TREQUINSIN; UNCLASSIFIED DRUG; VINPOCETINE;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUMINESCENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BENZOIC ACIDS; CELL LINE; CHO CELLS; CRICETINAE; CYCLIC GMP; DRUG INTERACTIONS; ENZYME INHIBITORS; GENES, REPORTER; MALE; MICE; MICE, INBRED STRAINS; TRANSFECTION;

EID: 27844464469     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.017608     Document Type: Article

References (26)

1. Alonso-Alija C, Heil M, Flubacher D, Naab P, Stasch JP, Wunder F, Dembowsky K, Perzborn E, and Stahl E (2001), inventors; Bayer AG, assignee. Novel dicarboxylic acid derivatives with pharmaceutical properties. World patent WO2001018780-A. 2001 March 22.
2. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748.
3. Bernabeu R, Schmitz P, Faillace MP, Izquierdo I, and Medina JH (1996) Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 7:585-588.
4. Bischoff E (2004) Potency, selectivity and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16:S11-S14.
5. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, and Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092.
6. Conti M and Jin SL (2001) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
7. Corbin JD and Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453-459.
8. Fischer DA, Smith JF, Pillar JS, Denis SHS, and Cheng JB (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
9. Francis SH, Turko IV, and Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
10. Garthwaite J (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14:60-67.
11. Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, et al. (1998) Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet 103:386-392.
12. Hendrix M (2005) Selective inhibitors of cGMP phosphodiesterases as procognitive agents. BMC Pharmacol 5 (Suppl 1):S5.
13. Hendrix M, Bärfacker L, Erb C, Hafner FT, Heckroth H, Schauss D, Tersteegen A, van der Stay FJ, and van Kampen M (2004), inventors; Bayer Healthcare AG, assignee. 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines. World patent WO2004099211-A. 2004 Nov 18.
14. Marko D, Merz KH, Kunz C, Muller A, Tarasova N, and Eisenbrand G (2002) Intracellular localization of 7-benzylamino-6-chloro-2-piperazino-4- pyrrolidinopteridine in membrane structures impeding the inhibition of cytosolic cyclic AMP-specific phosphodiesterase. Biochem Pharmacol 63:669-676.
15. Pon DJ, Plant M, Tkach J, Boulet L, Muise E, Allen RA, and Rodger IW (1998) Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Cell Biochem Biophys 29:159-178.
16. Prickaerts J, de Vente J, Honig W, Steinbusch HW, and Blokland A (2002) cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol 436:83-87.
17. Rentero C, Monfort A, and Puigdomenech P (2003) Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 301:686-692.
18. Soderling SH, Bayuga SJ, and Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558.
19. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
20. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiß U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature (Lond) 410:212-215.
21. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, et al. (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136:773-783.
22. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, and Fürstner C (2001) NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Lett 11:781-784.
23. van Staveren WC, Glick J, Markerink-van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW, and de Vente J (2002) Cloning and localization of the cGMPspecific phosphodiesterase type 9 in the rat brain. J Neurocytol 31:729-741.
24. Wang P, Wu P, Egan RW, and Billah MM (2003) Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314:15-27.
25. Wunder F, Stasch JP, Hütter J, Alonso-Alija C, Hüser J, and Lohrmann E (2005) A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the NO/cGMP pathway. Analyt Biochem 339:104-112.
26. Yamada K, Hiramatsu M, Noda Y, Mamiya T, Murai M, Kameyama T, Komori Y, Nikai T, Sugihara H, and Nabeshima T (1996) Role of nitric oxide and cyclic GMP in the dizolcipine-induced impairment of spontaneous alternation behaviour in mice. Neuroscience 74:365-374.